Pliant Therapeutics (NASDAQ: PLRX) announced it has dosed the first patient in the FORTIFY Phase 1b clinical trial expansion, evaluating ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE